SEC Form 4 · accession 0001626533-18-000003
Cell MedX Corp. · CMXC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley S Hargreaves
Officer — VP, Technology and Operations · Director · 10% Owner
Period of report
Sep 26, 2016
Accepted (ET)
Aug 24, 2018 · 2:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001493712
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1,F6 | $0.05 | Sep 26, 2016 | J | 1,250,000 | D | — | — | Common Stock | 1,250,000 | 0 | D |
| Stock Options (Right to Buy)F2,F6 | $0.05 | Sep 26, 2016 | J | 1,250,000 | D | — | — | Common Stock | 1,250,000 | 0 | D |
| Stock Options (Right to Buy)F3,F6 | $0.05 | Sep 26, 2016 | J | 1,250,000 | D | — | — | Common Stock | 1,250,000 | 0 | D |
| Stock Options (Right to Buy)F4,F6 | $0.05 | Sep 26, 2016 | J | 2,500,000 | D | — | — | Common Stock | 2,500,000 | 0 | D |
| Stock Options (Right to Buy)F5,F6 | $0.05 | Sep 26, 2016 | J | 2,500,000 | D | — | — | Common Stock | 2,500,000 | 0 | D |
Explanation of responses
- F1The Options were to vest upon the completion of first clinical trial and delivery of final white paper for the first clinical trial.
- F2The Options were to vest upon the design and commencement of the second clinical trial.
- F3The Options were to vest upon the completion of second clinical trial and delivery of final white paper for the second clinical trial.
- F4The Options were to vest upon the design and commencement of the third clinical trial.
- F5The Options were to vest upon the completion of the third clinical trial and delivery of final white paper for the third clinical trial.
- F6Options that would have vested were to expire 5 years after vesting. Options that have not vested would have expired on 12/31/2019.
Remarks
Disposition is associated with the cancellation of the unvested portion of the options originally granted to Mr. Hargreaves by the Issuer pursuant to the Option Agreement between the Company and Mr. Hargreaves dated for reference November 25, 2014